Role of Bcl-3 in solid tumors

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Maldonado, Vilma ^a   Melendez Zajgla, Jorge ^b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b Institute of Genomic Medicine (INMEGEN)   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 3; STAT3 PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; COLORECTAL CANCER; DIAGNOSTIC VALUE; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; NASOPHARYNX CANCER; NONHUMAN; ONCOGENE; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; B-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 84155176736     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-152     Document Type: Review

References (84)

1. Bours V, Villalobos J, Burd PR, Kelly K, Siebenlist U. Cloning of a mitogen-inducible gene encoding a kappa B DNA-binding protein with homology to the rel oncogene and to cell-cycle motifs. Nature 1990, 348(6296):76-80. 10.1038/348076a0, 2234062.
2. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990, 60(6):991-997. 10.1016/0092-8674(90)90347-H, 2180580.
3. Tanaka S, Nishigaki H, Nakagawa H, Okuda T, Nishida K, Tsuda S, Taniwaki M, Imanishi H, Misawa S, Kashima K, et al. Reciprocal t(14;19)(q32.3;q13.1) in a patient with B-cell lymphoma. Cancer Genet Cytogenet 1990, 49(2):219-224. 10.1016/0165-4608(90)90144-Y, 2208056.
4. van Krieken JH, McKeithan TW, Raghoebier S, Medeiros LJ, Kluin PM, Raffeld M. Chromosomal translocation t(14;19) as indicated by bcl-3 rearrangement is a rare phenomenon in non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a molecular genetic analysis of 176 cases. Leukemia 1990, 4(12):811-812.
5. Kerr LD, Duckett CS, Wamsley P, Zhang Q, Chiao P, Nabel G, McKeithan TW, Baeuerle PA, Verma IM. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes Dev 1992, 6(12A):2352-2363. 10.1101/gad.6.12a.2352, 1459457.
6. Wulczyn FG, Naumann M, Scheidereit C. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature 1992, 358(6387):597-599. 10.1038/358597a0, 1501714.
7. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993, 72(5):729-739. 10.1016/0092-8674(93)90401-B, 8453667.
8. Franzoso G, Bours V, Azarenko V, Park S, Tomita-Yamaguchi M, Kanno T, Brown K, Siebenlist U. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. Embo J 1993, 12(10):3893-3901. 413672, 8404857.
9. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev 1993, 7(7B):1354-1363. 10.1101/gad.7.7b.1354, 8330739.
10. Inoue J, Takahara T, Akizawa T, Hino O. Bcl-3, a member of the I kappa B proteins, has distinct specificity towards the Rel family of proteins. Oncogene 1993, 8(8):2067-2073.
11. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C. NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. Embo J 1999, 18(17):4766-4778. 10.1093/emboj/18.17.4766, 1171549, 10469655.
12. Brenne AT, Fagerli UM, Shaughnessy JD, Vatsveen TK, Ro TB, Hella H, Zhan F, Barlogie B, Sundan A, Borset M, et al. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol 2009, 82(5):354-363. 10.1111/j.1600-0609.2009.01225.x, 2704939, 19191868.
13. Rebollo A, Dumoutier L, Renauld JC, Zaballos A, Ayllon V, Martinez AC. Bcl-3 expression promotes cell survival following interleukin-4 deprivation and is controlled by AP1 and AP1-like transcription factors. Mol Cell Biol 2000, 20(10):3407-3416. 10.1128/MCB.20.10.3407-3416.2000, 85633, 10779330.
14. Elliott SF, Coon CI, Hays E, Stadheim TA, Vincenti MP. Bcl-3 is an interleukin-1-responsive gene in chondrocytes and synovial fibroblasts that activates transcription of the matrix metalloproteinase 1 gene. Arthritis Rheum 2002, 46(12):3230-3239. 10.1002/art.10675, 12483727.
15. Hu X, Nesic-Taylor O, Qiu J, Rea HC, Fabian R, Rassin DK, Perez-Polo JR. Activation of nuclear factor-kappaB signaling pathway by interleukin-1 after hypoxia/ischemia in neonatal rat hippocampus and cortex. J Neurochem 2005, 93(1):26-37. 10.1111/j.1471-4159.2004.02968.x, 15773902.
16. Brocke-Heidrich K, Ge B, Cvijic H, Pfeifer G, Loffler D, Henze C, McKeithan TW, Horn F. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 2006, 25(55):7297-7304. 10.1038/sj.onc.1209711, 16732314.
17. Kuwata H, Watanabe Y, Miyoshi H, Yamamoto M, Kaisho T, Takeda K, Akira S. IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-alpha production in macrophages. Blood 2003, 102(12):4123-4129. 10.1182/blood-2003-04-1228, 12907458.
18. Folco EJ, Rocha VZ, Lopez-Ilasaca M, Libby P. Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10. J Biol Chem 2009, 284(38):25569-25575. 10.1074/jbc.M109.019786, 2757958, 19617629.
19. Valenzuela JO, Hammerbeck CD, Mescher MF. Cutting Edge: Bcl-3 Up-Regulation by Signal 3 Cytokine (IL-12) Prolongs Survival of Antigen-Activated CD8 T Cells. J Immunol 2005, 174(2):600-604.
20. Maldonado V, Espinosa M, Pruefer F, Patino N, Ceballos-Canciono G, Urzua U, Juretic N, Melendez-Zajgla J. Gene regulation by BCL3 in a cervical cancer cell line. Folia Biol (Praha) 2010, 56(4):183-193.
21. Kung CP, Meckes DG, Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol 2011, 85(9):4399-4408. 10.1128/JVI.01703-10, 3126279, 21307189.
22. Brasier AR, Lu M, Hai T, Lu Y, Boldogh I. NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence. J Biol Chem 2001, 276(34):32080-32093. 10.1074/jbc.M102949200, 11387332.
23. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol 2003, 23(13):4713-4727. 10.1128/MCB.23.13.4713-4727.2003, 164841, 12808109.
24. Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM, Zimmerman GA. Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J Cell Biol 1999, 144(1):175-184. 10.1083/jcb.144.1.175, 2148114, 9885253.
25. Kraiss LW, Weyrich AS, Alto NM, Dixon DA, Ennis TM, Modur V, McIntyre TM, Prescott SM, Zimmerman GA. Fluid flow activates a regulator of translation, p70/p85 S6 kinase, in human endothelial cells. Am J Physiol Heart Circ Physiol 2000, 278(5):H1537-1544.
26. Viatour P, Dejardin E, Warnier M, Lair F, Claudio E, Bureau F, Marine JC, Merville MP, Maurer U, Green D, et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 2004, 16(1):35-45. 10.1016/j.molcel.2004.09.004, 15469820.
27. Garate M, Wani AA, Li G. The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med 2010, 48(12):1601-1609. 10.1016/j.freeradbiomed.2010.03.003, 20226854.
28. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006, 125(4):665-677. 10.1016/j.cell.2006.03.041, 16713561.
29. Keutgens A, Shostak K, Close P, Zhang X, Hennuy B, Aussems M, Chapelle JP, Viatour P, Gothot A, Fillet M, et al. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. Mol Cell Biol 2010, 30(16):4006-4021. 10.1128/MCB.01600-09, 2916444, 20547759.
30. Keutgens A, Zhang X, Shostak K, Robert I, Olivier S, Vanderplasschen A, Chapelle JP, Viatour P, Merville MP, Bex F, et al. BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1. J Biol Chem 2010, 285(33):25831-25840. 10.1074/jbc.M110.112128, 2919145, 20558726.
31. Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer 2011, 128(10):2274-2283. 10.1002/ijc.25575, 20658525.
32. Wickstrom SA, Masoumi KC, Khochbin S, Fassler R, Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. Embo J 2010, 29(1):131-144. 10.1038/emboj.2009.317, 2775896, 19893491.
33. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature 1992, 359(6393):339-342. 10.1038/359339a0, 1406939.
34. Watanabe N, Iwamura T, Shinoda T, Fujita T. Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. Embo J 1997, 16(12):3609-3620. 10.1093/emboj/16.12.3609, 1169985, 9218802.
35. Caamano JH, Perez P, Lira SA, Bravo R. Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol Cell Biol 1996, 16(4):1342-1348. 231118, 8657107.
36. Andrews N, Helliwell T, Walker C, Jones AS. Differing expression of bax and bcl-3 may influence the different cure rates in mouth and orophayrngeal cancer. Clin Otolaryngol 2000, 25(6):570-576.
37. Watanabe N, Wachi S, Fujita T. Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination. J Biol Chem 2003, 278(28):26102-26110. 10.1074/jbc.M303518200, 12730195.
38. Zhao Y, Ramakrishnan A, Kim KE, Rabson AB. Regulation of Bcl-3 through interaction with the Lck tyrosine kinase. Biochem Biophys Res Commun 2005, 335(3):865-873. 10.1016/j.bbrc.2005.07.162, 16099425.
39. Yang J, Williams RS, Kelly DP. Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha. Mol Cell Biol 2009, 29(15):4091-4102. 10.1128/MCB.01669-08, 2715798, 19451226.
40. Choi HJ, Lee JM, Kim H, Nam HJ, Shin HJ, Kim D, Ko E, Noh DY, Kim KI, Kim JH, et al. Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer. Biochem Biophys Res Commun 2010, 400(3):396-402. 10.1016/j.bbrc.2010.08.084, 20800578.
41. Kabuta T, Hakuno F, Cho Y, Yamanaka D, Chida K, Asano T, Wada K, Takahashi S. Insulin receptor substrate-3, interacting with Bcl-3, enhances p50 NF-kappaB activity. Biochem Biophys Res Commun 2010, 394(3):697-702. 10.1016/j.bbrc.2010.03.054, 20226764.
42. Chan KK, Shen L, Au WY, Yuen HF, Wong KY, Guo T, Wong ML, Shimizu N, Tsuchiyama J, Kwong YL, et al. Interleukin-2 induces NF-kappaB activation through BCL10 and affects its subcellular localization in natural killer lymphoma cells. J Pathol 2010, 221(2):164-174. 10.1002/path.2699, 20235165.
43. Au WY, Horsman DE, Ohno H, Klasa RJ, Gascoyne RD. Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas. Leuk Lymphoma 2002, 43(4):813-816. 10.1080/10428190290016935, 12153169.
44. Canoz O, Rassidakis GZ, Admirand JH, Medeiros LJ. Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol 2004, 17(8):911-917. 10.1038/modpathol.3800140, 15105810.
45. Schlette E, Rassidakis GZ, Canoz O, Medeiros LJ. Expression of bcl-3 in chronic lymphocytic leukemia correlates with trisomy 12 and abnormalities of chromosome 19. Am J Clin Pathol 2005, 123(3):465-471. 10.1309/6Q27Q3NDGV8LW1BU, 15716244.
46. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000, 19(9):1123-1131. 10.1038/sj.onc.1203412, 10713699.
47. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003, 63(23):8293-8301.
48. Pallares J, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J, Matias-Guiu X. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol 2004, 204(5):569-577. 10.1002/path.1666, 15481028.
49. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18(49):6938-6947. 10.1038/sj.onc.1203221, 10602468.
50. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2(4):301-310. 10.1038/nrc780, 12001991.
51. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011, 12(8):715-723. 10.1038/ni.2060, 21772280.
52. Hovelmeyer N, Wunderlich FT, Massoumi R, Jakobsen CG, Song J, Worns MA, Merkwirth C, Kovalenko A, Aumailley M, Strand D, et al. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J Exp Med 2007, 204(11):2615-2627. 10.1084/jem.20070318, 2118471, 17923499.
53. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, (39 Database):D945-950.
54. Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003, 23(16):5738-5754. 10.1128/MCB.23.16.5738-5754.2003, 166341, 12897145.
55. Pratt MA, Bishop TE, White D, Yasvinski G, Menard M, Niu MY, Clarke R. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 2003, 23(19):6887-6900. 10.1128/MCB.23.19.6887-6900.2003, 193930, 12972607.
56. Paine E, Scheinman RI, Baldwin AS, Raab-Traub N. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol 1995, 69(7):4572-4576. 189208, 7769726.
57. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995, 69(7):4390-4398. 189180, 7769701.
58. Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, Tepper JE, O'Neil BH. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 2010, 78(3-4):181-188. 10.1159/000313697, 2914399, 20414006.
59. Ong ST, Hackbarth ML, Degenstein LC, Baunoch DA, Anastasi J, McKeithan TW. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene 1998, 16(18):2333-2343. 10.1038/sj.onc.1201771, 9620550.
60. Rangelova S, Kirschnek S, Strasser A, Hacker G. FADD and the NF-kappaB family member Bcl-3 regulate complementary pathways to control T-cell survival and proliferation. Immunology 2008, 125(4):549-557. 10.1111/j.1365-2567.2008.02869.x, 2612552, 18557791.
61. Mitchell TC, Teague TK, Hildeman DA, Bender J, Rees WA, Kedl RM, Swanson B, Kappler JW, Marrack P. Stronger correlation of bcl-3 than bcl-2, bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival. Ann N Y Acad Sci 2002, 975:114-131. 10.1111/j.1749-6632.2002.tb05946.x, 12538159.
62. Mitchell TC, Thompson BS, Trent JO, Casella CR. A short domain within Bcl-3 is responsible for its lymphocyte survival activity. Ann N Y Acad Sci 2002, 975:132-147. 10.1111/j.1749-6632.2002.tb05947.x, 12538160.
63. Bauer A, Villunger A, Labi V, Fischer SF, Strasser A, Wagner H, Schmid RM, Hacker G. The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells. Proc Natl Acad Sci USA 2006, 103(29):10979-10984. 10.1073/pnas.0603625103, 1544160, 16832056.
64. Baguley BC. The paradox of cancer cell apoptosis. Front Biosci 2011, 16:1759-1767. 10.2741/3819, 21196262.
65. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, Bours V. NF- kappa B2/p100 induces Bcl-2 expression. Leukemia 2003, 17(7):1349-1356. 10.1038/sj.leu.2402982, 12835724.
66. Kashatus D, Cogswell P, Baldwin AS. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2006, 20(2):225-235. 10.1101/gad.1352206, 1356113, 16384933.
67. Meek DW. Tumour suppression by p53: a role for the DNA damage response?. Nat Rev Cancer 2009, 9:714-723.
68. Ahmed SU, Milner J. Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One 2009, 4(10):e7305. 10.1371/journal.pone.0007305, 2752166, 19806201.
69. Zamora R, Espinosa M, Ceballos-Cancino G, Segura B, Maldonado V, Melendez-Zajgla J. Depletion of the oncoprotein Bcl-3 induces centrosome amplification and aneuploidy in cancer cells. Mol Cancer 2010, 9:223. 10.1186/1476-4598-9-223, 2933622, 20731879.
70. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008, 68:3077-3080. discussion 3080, 10.1158/0008-5472.CAN-07-3293, 18451130.
71. Lagunas-Martinez A, Madrid-Marina V, Gariglio P. Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. Biochim Biophys Acta 2010, 1805(1):6-16.
72. Barry SP, Townsend PA, Knight RA, Scarabelli TM, Latchman DS, Stephanou A. STAT3 modulates the DNA damage response pathway. Int J Exp Pathol 2010, 91(6):506-514. 10.1111/j.1365-2613.2010.00734.x, 3010549, 20804538.
73. Courapied S, Sellier H, de Carne Trecesson S, Vigneron A, Bernard AC, Gamelin E, Barre B, Coqueret O. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem 2010, 285(35):26765-26778. 10.1074/jbc.M109.092304, 2930675, 20516069.
74. Bito T, Sumita N, Masaki T, Shirakawa T, Ueda M, Yoshiki R, Tokura Y, Nishigori C. Ultraviolet light induces Stat3 activation in human keratinocytes and fibroblasts through reactive oxygen species and DNA damage. Experimental dermatology 2010, 19(7):654-660. 10.1111/j.1600-0625.2010.01084.x, 20456494.
75. Kreisel D, Sugimoto S, Tietjens J, Zhu J, Yamamoto S, Krupnick AS, Carmody RJ, Gelman AE. Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis. J Clin Invest 2011, 121(1):265-276. 10.1172/JCI42596, 3007142, 21157041.
76. Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol 2001, 21(24):8428-8436. 10.1128/MCB.21.24.8428-8436.2001, 100006, 11713278.
77. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T, Pfeifer A, Fassler R, Bosserhoff AK. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009, 206(1):221-232. 10.1084/jem.20082044, 2626666, 19124656.
78. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 1999, 18(52):7423-7431. 10.1038/sj.onc.1203104, 10602501.
79. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011, (39 Database):D561-568.
80. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22(2):195-201. 10.1093/bioinformatics/bti770, 16301204.
81. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006, 9(4):287-300. 10.1016/j.ccr.2006.03.003, 16616334.
82. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14(5):518-527. 10.1038/nm1764, 18438415.
83. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001, 98(3):1176-1181. 10.1073/pnas.98.3.1176, 14728, 11158614.
84. Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006, 66(2):820-827. 10.1158/0008-5472.CAN-05-2445, 16424014.